Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894765079> ?p ?o ?g. }
- W2894765079 endingPage "1729" @default.
- W2894765079 startingPage "1720" @default.
- W2894765079 abstract "Objective To evaluate the efficacy and safety of tocilizumab, an interleukin-6 receptor antibody, in patients with adult-onset Still’s disease. Methods In this double-blind, randomised, placebo-controlled phase III trial, 27 patients with adult-onset Still’s disease refractory to glucocorticoids were randomised to tocilizumab at a dose of 8 mg/kg or placebo given intravenously every 2 weeks during the 12-week, double-blind phase. Patients received open-label tocilizumab for 40 weeks subsequently. The primary outcome was American College of Rheumatology (ACR) 50 response at week 4. The secondary outcomes included ACR 20/50/70, systemic feature score, glucocorticoid dose and adverse events at each point. Results In the full analysis set, ACR50 response at week 4 was achieved in 61.5% (95% CI 31.6 to 86.1) in the tocilizumab group and 30.8% (95% CI 9.1 to 61.4) in the placebo group (p=0.24). The least squares means for change in systemic feature score at week 12 were –4.1 in the tocilizumab group and –2.3 in the placebo group (p=0.003). The dose of glucocorticoids at week 12 decreased by 46.2% in the tocilizumab group and 21.0% in the placebo group (p=0.017). At week 52, the rates of ACR20, ACR50 and ACR70 were 84.6%, 84.6% and 61.5%, respectively, in both groups. Serious adverse events in all participants who received one dose of tocilizumab were infections, aseptic necrosis in the hips, exacerbation of adult-onset Still’s disease, drug eruption and anaphylactic shock. Conclusion The study suggests that tocilizumab is effective in adult-onset Still’s disease, although the primary endpoint was not met and solid conclusion was not drawn." @default.
- W2894765079 created "2018-10-12" @default.
- W2894765079 creator A5010820894 @default.
- W2894765079 creator A5015953107 @default.
- W2894765079 creator A5039165431 @default.
- W2894765079 creator A5040347971 @default.
- W2894765079 creator A5058629132 @default.
- W2894765079 creator A5072897343 @default.
- W2894765079 creator A5080388789 @default.
- W2894765079 creator A5083314956 @default.
- W2894765079 creator A5083709357 @default.
- W2894765079 date "2018-10-02" @default.
- W2894765079 modified "2023-10-18" @default.
- W2894765079 title "Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial" @default.
- W2894765079 cites W1517960418 @default.
- W2894765079 cites W1614943507 @default.
- W2894765079 cites W1685776505 @default.
- W2894765079 cites W1779387069 @default.
- W2894765079 cites W1971823659 @default.
- W2894765079 cites W1993049580 @default.
- W2894765079 cites W2008945784 @default.
- W2894765079 cites W2011589128 @default.
- W2894765079 cites W2017213437 @default.
- W2894765079 cites W2035505806 @default.
- W2894765079 cites W2049803113 @default.
- W2894765079 cites W2050446994 @default.
- W2894765079 cites W2074391948 @default.
- W2894765079 cites W2087433200 @default.
- W2894765079 cites W2087769239 @default.
- W2894765079 cites W2092625242 @default.
- W2894765079 cites W2093315648 @default.
- W2894765079 cites W2103495299 @default.
- W2894765079 cites W2107770711 @default.
- W2894765079 cites W2113603648 @default.
- W2894765079 cites W2120852203 @default.
- W2894765079 cites W2125372614 @default.
- W2894765079 cites W2134911659 @default.
- W2894765079 cites W2142659423 @default.
- W2894765079 cites W2143826719 @default.
- W2894765079 cites W2155626936 @default.
- W2894765079 cites W2155947420 @default.
- W2894765079 cites W2159106700 @default.
- W2894765079 cites W2160656833 @default.
- W2894765079 cites W2162564777 @default.
- W2894765079 cites W2166106092 @default.
- W2894765079 cites W2325512805 @default.
- W2894765079 cites W2415396904 @default.
- W2894765079 cites W2528297804 @default.
- W2894765079 cites W2767454393 @default.
- W2894765079 cites W2788608061 @default.
- W2894765079 cites W4253312660 @default.
- W2894765079 doi "https://doi.org/10.1136/annrheumdis-2018-213920" @default.
- W2894765079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30279267" @default.
- W2894765079 hasPublicationYear "2018" @default.
- W2894765079 type Work @default.
- W2894765079 sameAs 2894765079 @default.
- W2894765079 citedByCount "117" @default.
- W2894765079 countsByYear W28947650792018 @default.
- W2894765079 countsByYear W28947650792019 @default.
- W2894765079 countsByYear W28947650792020 @default.
- W2894765079 countsByYear W28947650792021 @default.
- W2894765079 countsByYear W28947650792022 @default.
- W2894765079 countsByYear W28947650792023 @default.
- W2894765079 crossrefType "journal-article" @default.
- W2894765079 hasAuthorship W2894765079A5010820894 @default.
- W2894765079 hasAuthorship W2894765079A5015953107 @default.
- W2894765079 hasAuthorship W2894765079A5039165431 @default.
- W2894765079 hasAuthorship W2894765079A5040347971 @default.
- W2894765079 hasAuthorship W2894765079A5058629132 @default.
- W2894765079 hasAuthorship W2894765079A5072897343 @default.
- W2894765079 hasAuthorship W2894765079A5080388789 @default.
- W2894765079 hasAuthorship W2894765079A5083314956 @default.
- W2894765079 hasAuthorship W2894765079A5083709357 @default.
- W2894765079 hasBestOaLocation W28947650791 @default.
- W2894765079 hasConcept C126322002 @default.
- W2894765079 hasConcept C141071460 @default.
- W2894765079 hasConcept C142724271 @default.
- W2894765079 hasConcept C168563851 @default.
- W2894765079 hasConcept C197934379 @default.
- W2894765079 hasConcept C198451711 @default.
- W2894765079 hasConcept C203092338 @default.
- W2894765079 hasConcept C204787440 @default.
- W2894765079 hasConcept C27081682 @default.
- W2894765079 hasConcept C2777014857 @default.
- W2894765079 hasConcept C2777178219 @default.
- W2894765079 hasConcept C2777575956 @default.
- W2894765079 hasConcept C71924100 @default.
- W2894765079 hasConcept C90924648 @default.
- W2894765079 hasConceptScore W2894765079C126322002 @default.
- W2894765079 hasConceptScore W2894765079C141071460 @default.
- W2894765079 hasConceptScore W2894765079C142724271 @default.
- W2894765079 hasConceptScore W2894765079C168563851 @default.
- W2894765079 hasConceptScore W2894765079C197934379 @default.
- W2894765079 hasConceptScore W2894765079C198451711 @default.
- W2894765079 hasConceptScore W2894765079C203092338 @default.
- W2894765079 hasConceptScore W2894765079C204787440 @default.
- W2894765079 hasConceptScore W2894765079C27081682 @default.
- W2894765079 hasConceptScore W2894765079C2777014857 @default.